Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months Adicet Bio NASDAQ: ACET repor...
Topics
Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months Adicet Bio NASDAQ: ACET reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis.
Related QATS news
- Clorox, General Mills, and Constellation Brands Are Down Between 22% and 33%. Here's the Stock to Bu...
- Berkshire Hathaway Is Buying Up Shares of This Beaten-Down Stock. Should You Invest Too? From Sept....
- History Says Coca-Cola Stock Holds Up When the S&P 500 Falls Since 1980, the S&P 500 has logged a n...
- NuScale vs. Oklo vs. GE Vernova: Ranking 3 Nuclear Stocks By Backlog, Not Hype. These stocks are be...